Las personas que usan Zepbound o Mounjaro, los medicamentos agonistas duales, pierden un promedio de alrededor del 20% de su peso corporal, mientras que quienes toman Ozempic o Wegovy, los frmacos agonistas simples, pierden un promedio de alrededor del 14% de su peso corporal
The Phase 3 data coming out of Eli Lilly's TRIUMPH program shows weight loss numbers that make semaglutide and tirzepatide look modest by comparison
Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man
Feel free to leave a comment below or share your story
Technically, when the FDA first yanked tirzepatide off its shortage list in October 2024, both 503As and 503Bs could no longer legally make copycats (with one notable exception for the smaller 503As, who could still fill individual prescriptions if there was a medical reason the patient needed a slightly different version than the brand-name drugmore on this later)
In SURMOUNT-5, tirzepatide produced 20.2% mean weight loss versus 13.7% on semaglutide at 72 weeks
